WHO advises against weight-loss drugs for children under 10

The World Health Organization issued guidance recommending against the use of weight-loss drugs, including GLP-1 agonists like Mounjaro and Wegovy, in children under 10. This is a policy statement, not a new clinical trial result, and its impact is primarily on pediatric prescribing practices and regulatory discussions. The guidance may influence future approvals and insurance coverage, but immediate market effects are limited.